Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 8622701 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Mohammadi M, et al. (1996) Identification of six novel autophosphorylation sites on fibroblast growth factor receptor 1 and elucidation of their importance in receptor activation and signal transduction. Mol Cell Biol 16, 977-89 8622701
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y463-p - FGFR1 (human) ▲
Orthologous residues
FGFR1 (human): Y463‑p, FGFR1 iso21 (human): Y494‑p, FGFR1 (mouse): Y463‑p, FGFR1 (rat): Y370‑p, FGFR1 iso2 (rat): Y463‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody, phosphoamino acid analysis, western blotting
 Relevant cell lines - cell types - tissues:  L6 (myoblast), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  Phosphoantibody is anti-phosphotyrosine in conjunction with point mutants.
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE FGFR1 (human)
 Comments:  Y766 was missing from this construct and thus was not detected.
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase

Y583-p - FGFR1 (human) ▲
Orthologous residues
FGFR1 (human): Y583‑p, FGFR1 iso21 (human): Y614‑p, FGFR1 (mouse): Y583‑p, FGFR1 (rat): Y490‑p, FGFR1 iso2 (rat): Y583‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody, phosphoamino acid analysis, western blotting
 Relevant cell lines - cell types - tissues:  L6 (myoblast), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  Phosphoantibody is anti-phosphotyrosine in conjunction with point mutants.
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE FGFR1 (human)
 Comments:  Y766 was missing from this construct and thus was not detected.
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase

Y585-p - FGFR1 (human) ▲
Orthologous residues
FGFR1 (human): Y585‑p, FGFR1 iso21 (human): Y616‑p, FGFR1 (mouse): Y585‑p, FGFR1 (rat): Y492‑p, FGFR1 iso2 (rat): Y585‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody, phosphoamino acid analysis, western blotting
 Relevant cell lines - cell types - tissues:  L6 (myoblast), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  Phosphoantibody is anti-phosphotyrosine in conjunction with point mutants.
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE FGFR1 (human)
 Comments:  Y766 was missing from this construct and thus was not detected.
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase

Y653-p - FGFR1 (human) ▲
Orthologous residues
FGFR1 (human): Y653‑p, FGFR1 iso21 (human): Y684‑p, FGFR1 (mouse): Y653‑p, FGFR1 (rat): Y560‑p, FGFR1 iso2 (rat): Y653‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody, phosphoamino acid analysis, western blotting
 Relevant cell lines - cell types - tissues:  L6 (myoblast), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  Phosphoantibody is anti-phosphotyrosine in conjunction with point mutants.
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE FGFR1 (human)
 Comments:  Y766 was missing from this construct and thus was not detected.
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced, phosphorylation
 Effect of modification (process):  cell differentiation, altered, cell growth, altered, cell motility, altered
 Comments:  Double Y->F mutant has less neurite outgrowth in PC12 cells (differentiation), and less cell proliferation in L-6 cells.

Y654-p - FGFR1 (human) ▲
Orthologous residues
FGFR1 (human): Y654‑p, FGFR1 iso21 (human): Y685‑p, FGFR1 (mouse): Y654‑p, FGFR1 (rat): Y561‑p, FGFR1 iso2 (rat): Y654‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody, phosphoamino acid analysis, western blotting
 Relevant cell lines - cell types - tissues:  L6 (myoblast), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  Phosphoantibody is anti-phosphotyrosine in conjunction with point mutants.
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE FGFR1 (human)
 Comments:  Y766 was missing from this construct and thus was not detected.
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced, phosphorylation
 Effect of modification (process):  cell differentiation, altered, cell growth, altered, cell motility, altered
 Comments:  Double Y->F mutant has less neurite outgrowth in PC12 cells (differentiation), and less cell proliferation in L-6 cells.

Y730-p - FGFR1 (human) ▲
Orthologous residues
FGFR1 (human): Y730‑p, FGFR1 iso21 (human): Y761‑p, FGFR1 (mouse): Y730‑p, FGFR1 (rat): Y637‑p, FGFR1 iso2 (rat): Y730‑p
Characterization
 Methods used to characterize site in vivo:  [32P] bio-synthetic labeling, mutation of modification site, peptide sequencing, phospho-antibody, phosphoamino acid analysis, western blotting
 Relevant cell lines - cell types - tissues:  L6 (myoblast), PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Species studied:  rat
 Comments:  Phosphoantibody is anti-phosphotyrosine in conjunction with point mutants.
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE FGFR1 (human)
 Comments:  Y766 was missing from this construct and thus was not detected.
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase

Y766-p - FGFR1 (human) ▲
Orthologous residues
FGFR1 (human): Y766‑p, FGFR1 iso21 (human): Y797‑p, FGFR1 (mouse): Y766‑p, FGFR1 (rat): Y673‑p, FGFR1 iso2 (rat): Y766‑p
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
aFGF increase


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.